COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
COLLEGIUM PHARMACEUTICAL, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$23.01−0.18 (-0.78%)
Close on Oct 19, 2026
- Market cap
- $746.92M
- P/E (TTM)
- 18.6
- Dividend yield
- –
COLLEGIUM PHARMACEUTICAL, INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Belbuca | $57.67M | $52.65M | $59.14M | $58.26M | $52.60M | $51.66M | $55.21M | $53.20M | $52.20M | $50.66M | $49.30M | $45.45M | 28.9% | +9.6% |
| Jornay PM | $46.06M | $38.89M | $45.89M | $41.80M | $32.63M | $28.54M | $29.28M | $7.96M | – | – | – | – | 23.0% | +41.2% |
| Xtampza ER | $45.01M | $50.77M | – | – | $52.61M | $47.64M | – | – | – | – | – | – | 22.5% | -14.4% |
| Nucynta ER | $15.72M | $18.23M | – | – | $19.95M | $19.69M | – | – | – | – | – | – | 7.9% | -21.2% |
| Nucynta IR | $14.36M | $26.08M | – | – | $26.50M | $27.42M | – | – | – | – | – | – | 7.2% | -45.8% |
| Azstarys | $12.91M | – | – | – | $0 | – | – | – | – | – | – | – | 6.5% | – |
| Symproic | $3.02M | $4.19M | – | $4.03M | $3.72M | $2.82M | $4.25M | $3.52M | $4.03M | $3.30M | $5.09M | $3.92M | 1.5% | -18.9% |
| Nucynta ER AG | $2.78M | $1.45M | – | – | $0 | $0 | – | – | – | – | – | – | 1.4% | – |
| Nucynta IR AG | $2.36M | $1.26M | – | – | $0 | $0 | – | – | – | – | – | – | 1.2% | – |
| Xtampza ER | – | – | – | $50.48M | $52.61M | $47.64M | $51.45M | $49.49M | $44.57M | $45.81M | $48.46M | $39.80M | – | – |
| Nucynta IR | – | – | – | $31.99M | $26.50M | $27.42M | $24.22M | $25.36M | $25.20M | $25.96M | $27.19M | $24.91M | – | – |
| Nucynta ER | – | – | – | $22.81M | $19.95M | $19.69M | $17.54M | $19.77M | $19.27M | $19.19M | $19.71M | $22.63M | – | – |
By region
From the segment and revenue-disaggregation notes of Collegium Pharmaceutical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.